April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Efficacy and Safety of Fixed Combinations of Prostaglandin Analogues with Timolol Maleate in Primary Open Angle Glaucoma and Ocular Hypertension
Author Affiliations & Notes
  • Enyr S. Arcieri
    Ophthalmology, University of Campinas, Campinas, Brazil
    Presidente Antônio Carlos University, Araguari, Brazil
  • Ana Cláudia A. Pereira
    Ophthalmology, UNIDERP, Campo Grande, Brazil
    Santa Casa de Campo Grande, Campo Grande, Brazil
  • Antônio E. Pereira
    Ophthalmology, UNIDERP, Campo Grande, Brazil
    Santa Casa de Campo Grande, Campo Grande, Brazil
  • Rafael S. Arcieri
    Ophthalmology, Hospital Ana Costa, Santos, Brazil
  • Footnotes
    Commercial Relationships  Enyr S. Arcieri, None; Ana Cláudia A. Pereira, None; Antônio E. Pereira, None; Rafael S. Arcieri, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 232. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Enyr S. Arcieri, Ana Cláudia A. Pereira, Antônio E. Pereira, Rafael S. Arcieri; Efficacy and Safety of Fixed Combinations of Prostaglandin Analogues with Timolol Maleate in Primary Open Angle Glaucoma and Ocular Hypertension. Invest. Ophthalmol. Vis. Sci. 2011;52(14):232.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of three fixed combination of prostaglandin analogues with timolol maleate currently available in Brazil [bimatoprost with timolol (BT) - Ganfort, latanoprost with timolol (LT) - Xalacom, and travoprost with timolol (TT) - Duo-Travatran] in primary open angle glaucoma (POAG) or ocular hypertension (OHT) subjects.

Methods: : Forty-six phakic patients (92 eyes) with POAG or OHT were enrolled in this prospective, randomized, masked-observer, parallel group study. Patients were randomized to use BT, LT or DT once daily for 2 months. Patients in each group were also randomized to instill the fixed combination at 8:00 am or 8:00 pm during the first 30-days period and after that they started the opposite medication time for the second 30-days period. Intraocular pressure (IOP) was measured at 8:00 am, 12:00 pm, and 4:00 pm at baseline and at the end of each treatment period. Unsolicited ocular adverse events were also recorded.

Results: : The baseline mean diurnal IOP was 21.84 ± 3.84 mmHg for BT, 21.82 ± 4.04 mmHg for LT, and 22.42 ± 3.90 mmHg for TT (p=0.7972). All fixed combinations significantly reduced IOP compared with baseline (p<0.00001). The mean diurnal IOP following therapy was 14.31 ± 1.71 mmHg for BT, 14.47 ± 2.39 mmHg for LT, and 14.27 ± 2.01 mmHg for TT at one month (p=0.9200); and 14.45 ± 1.81 mmHg for BT, 14.51 ± 2.62 mmHg for LT, and 14.13 ± 2.01 mmHg for TT at two months (p=0.7675). The IOP reduction did not differ statistically between groups at all time intervals (p>0.2015). Overall, 15 subjects complained about ocular adverse events at one month (6 for BT, 3 for LT and 6 for TT - p=0.1172), and 10 at two months (3 for BT, 2 for LT and 5 for TT - p=0.1334). The most commonly reported treatment-related adverse event was conjunctival hyperemia. At two months, BT (2) and TT (4) caused more ocular hyperemia than LT (0) (p=0.0356). There were no statistically significant differences between IOP reduction or incidence of treatment-related adverse event according to time of instilling the eye drops (morning or evening) among the groups (p>0.0676).

Conclusions: : This study suggests that BT, LT and TT, regardless if instilled at morning or at evening, have similar efficacy in POAG or OHT subjects.

Clinical Trial: : http://www.anzctr.org.au ACTRN12610001034022

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×